Abciximab and rt-PA in Acute Ischemic Stroke Treatment


Phase N/A Results

Trial Description

To evaluate the safety and potential benefits and abciximab administered in conjunction with half-dose rt-PA in acute ischemic stroke patients.


  • Abciximab (ReoPro®)Drug
    Intervention Desc: Intravenous platelet aggregation inhibitor, monoclonal antibody directed against the platelet glycoprotein GP IIb-IIIa receptor
  • Tissue plasminogen activator (Activase®)Drug
    Other Names: Alteplase; tPA
    Intervention Desc: Thrombolytic

Trial Design

Single-center, open-label, phase I, safety and efficacy study.

Patient Involvement

Patients with acute ischemic stroke were given a combination therapy of half-dose rt-PA (0.45 mg/kg) and abciximab (initial bolus of 0.25 mg/kg followed by an infusion of 0.125 µg/kg/min for 12 hours).


Type Measure Time Frame Safety Issue
Primary Frequency of symptomatic intracerebral hemorrhage at 24 hours.
Secondary NIHSS at discharge.


National Institute of Neurological Disorders and Stroke - NIH